Axsome Therapeutics (AXSM) Invested Capital (2015 - 2026)

Axsome Therapeutics' Invested Capital history runs 12 years deep, the most recent figure standing at $65.7 million for Q1 2026.

• In Q1 2026, Invested Capital fell 71.81% year-over-year to $65.7 million; the TTM figure through Mar 2026 stood at $65.7 million (down 71.81% YoY), while the FY2025 annual figure was $208.3 million, down 12.12% from the prior year.
• Invested Capital came in at $65.7 million for Q1 2026 at Axsome Therapeutics, down from $208.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $458.8 million in Q2 2023 to a low of $64.7 million in Q1 2022.
• A 5-year average of $240.2 million and a median of $233.2 million in 2025 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital jumped 316.34% in 2023 and slumped 71.81% in 2026, its largest moves.
• Axsome Therapeutics' Invested Capital stood at $204.6 million in 2022, then surged by 81.36% to $371.0 million in 2023, then plunged by 36.11% to $237.0 million in 2024, then decreased by 12.12% to $208.3 million in 2025, then sank by 68.44% to $65.7 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $65.7 million, $208.3 million, and $193.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison